These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28523947)

  • 1. Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y
    Mitrugno A; Rigg RA; Laschober NB; Ngo ATP; Pang J; Williams CD; Aslan JE; McCarty OJT
    Platelets; 2018 Jun; 29(4):383-394. PubMed ID: 28523947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine (Prozac) augments platelet activation mediated through protease-activated receptors.
    Dilks JR; Flaumenhaft R
    J Thromb Haemost; 2008 Apr; 6(4):705-8. PubMed ID: 18194419
    [No Abstract]   [Full Text] [Related]  

  • 3. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
    Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
    Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
    Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
    Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
    Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
    Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
    Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation.
    Tseng YL; Chiang ML; Lane HY; Su KP; Lai YC
    Thromb Res; 2013 Apr; 131(4):325-32. PubMed ID: 23490430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses.
    Shankar H; Murugappan S; Kim S; Jin J; Ding Z; Wickman K; Kunapuli SP
    Blood; 2004 Sep; 104(5):1335-43. PubMed ID: 15142872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y
    Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M
    Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
    Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of agonist-induced activation and inhibition for the regulation of purinergic receptor expression in human platelets.
    Koessler J; Trulley VN; Bosch A; Weber K; Koessler A; Boeck M; Kobsar A
    Thromb Res; 2018 Aug; 168():40-46. PubMed ID: 29902630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
    Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
    J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors.
    Badr Eslam R; Lang IM; Koppensteiner R; Calatzis A; Panzer S; Gremmel T
    Int J Cardiol; 2013 Sep; 168(1):403-6. PubMed ID: 23041015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
    Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
    Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
    Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
    Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
    Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.